You are here:

eluxadoline (Truberzi)

Advice

following a full submission

eluxadoline (Truberzi®) is not recommended for use within NHS Scotland.

Indication under review: in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).

Eluxadoline showed superiority over placebo in producing a composite response, which included abdominal pain response and stool consistency response, in patients with IBS-D.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: eluxadoline (Truberzi)
SMC Drug ID: 1292/18
Manufacturer: Allergan Ltd
Indication: in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).
BNF Category:
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 15 January 2018

Back